CD4 and neoplasm: Our data suggest that this enhanced antitumor efficacy is a consequence of reduced G‐MDSCs and Tregs within the TIME by Mito‐ATO, and a concomitant increase in functional tumor‐infiltrating cytotoxic CD4+ T cells.